Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Ample Liquidity ⢠Persistent Losses ⢠Dilution Risk IMNM has ample liquidity and minimal debt, but absent revenue, heavy losses, rapid cash burn, dilution reliance, and a high price-to-book valuation make it a high-risk investment.
Price Behavior
Key Price Behavior Insights: ⢠Lower highs ⢠Key support ⢠Reclaim resistance Support Level: $26.20â$26.80; lower support $25.00â$25.70 Resistance Level: $27.60 IMNM is up 7% over the last month but short-term momentum is weakening below $27.54; holding $26.20â$26.80 support is key, while reclaiming $27.60 would improve the outlook and a break below $26.20 risks $25.00â$25.70.
Sentiment & News
Key News Insights: ⢠FDA NDA Acceptance ⢠IM-1021 Catalyst ⢠Phase 3 Success Immunome's FDA-accepted varegacestat NDA and IM-1021 catalyst support upside into 2027, while argenx's positive Phase 3 VYVGART Hytrulo data strengthens its autoimmune-growth outlook.
AI Summary
IMNM is now primarily an April 2027 FDA/launch-execution investment on varegacestatânot an early-stage platform storyâso investors should weigh approval and desmoid-market uptake against accelerating cash burn and potential dilution if its ~$520M runway cannot bridge commercialization without another equity raise.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |